KDM1A and small cell lung carcinoma: A phase I multicentre, open-label study that investigated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the LSD1 inhibitor GSK2879552 in patients with relapsed or refractory SCLC was terminated due to a high incidence of adverse events and poor disease control [134].